Fig 1: YWHAG overexpression reverses the inhibitory effect of TXNDC9 silencing on the viability, proliferation, migration and invasiveness of lung adenocarcinoma cells. (A) mRNA and (B) protein expression levels of YWHAG were measured using reverse transcription-quantitative PCR and western blotting, respectively. ***P<0.001 vs. Oe-NC or Control. (C) Cell viability was detected using Cell Counting Kit-8 assay. *P<0.05, **P<0.01, ***P<0.001 vs. si-NC; #P<0.05 and ##P<0.01 vs. si-TXNDC9 + Oe-NC. (D and E) Proliferation was detected using colony formation assay. Magnification, ×4. ***P<0.001 vs. si-NC; ##P<0.01 vs. si-TXNDC9 + Oe-NC. (F and G) Wound healing and (H and I) Transwell assay were used to detect migration and invasiveness, respectively. ***P<0.001 vs. si-NC; ##P<0.01 vs. si-TXNDC9 + Oe-NC. NC, negative control; Oe, overexpression; si, small interfering RNA; TXNDC9, thioredoxin domain-containing protein 9; YWHAG, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein ?.
Fig 2: YWHAG overexpression reverses the promotive effects of TXNDC9 silencing on lung adenocarcinoma cells apoptosis. (A) Representative images and (B) quantitative analysis of the TUNEL assay used to examine apoptosis. (C) Protein expression levels of MMP2, MMP9, Bax and Bcl-2 were detected using western blot analysis. **P<0.01, ***P<0.001. MMP, matrix metalloproteinase; NC, negative control; oe, overexpression; si, small interfering; TXNDC9, thioredoxin domain-containing protein 9; YWHAG, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein ?.
Fig 3: TXNDC9 is upregulated in LUAD cells. (A) Encyclopedia of RNA Interactomes revealed that TXNDC9 was upregulated in LUAD. (B) Overall survival for high TXNDC9 expression and low TXNDC9 expression in LUAD cancer; + (low,1) represents one sample in low TXNDC9 expression group, + (high,1) represents one sample in high TXNDC9 expression group. Relative TXNDC9 (C) mRNA and (D) protein expression levels were measured using reverse transcription-quantitative PCR and western blotting, respectively. *P<0.05 and ***P<0.001. LUAD, lung adenocarcinoma; TXNDC9, thioredoxin domain-containing protein 9.
Fig 4: YWHAG is upregulated in lung adenocarcinoma and binds to TXNDC9. (A) mRNA and (B) protein expression levels of YWHAG were measured using reverse transcription-quantitative PCR and western blot, respectively. (C) According to STRING database, TXNDC9 and YWHAG are co-expressed and (D) Gene Expression Profiling Interactive Analysis revealed that TXNDC9 was positively correlated with YWHAG. (E) TXNDC9 and YWHAG were detected using co-IP. (F) Protein expression of YWHAG was measured using western blotting following si-TXNDC9 transfection. **P<0.01, ***P<0.001. IP, immunoprecipitation; si, small interfering; NC, negative control; TPM, transcripts per million; TXNDC9, thioredoxin domain-containing protein 9; YWHAG, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein ?.
Fig 5: TXNDC9 knockdown inhibits migration and invasion, and promotes apoptosis, of lung adenocarcinoma cells. (A) Wound healing and (B) quantitative analysis. (C) Transwell and (D) relative invasion rate. (E) TUNEL assay and (F) quantitative analysis. (G) Protein expression levels of MMP2, MMP9, Bax and Bcl-2 were detected using western blotting. **P<0.01, ***P<0.001. MMP, matrix metalloproteinase; NC, negative control; si, small interfering RNA; TXNDC9, thioredoxin domain-containing protein 9.
Supplier Page from Abcam for Anti-TXNDC9 antibody [EPR15238]